Login / Signup

Bronchopulmonary penetration of isavuconazole in lung transplant recipients.

Antonio F Caballero-BermejoIgnacio Darnaude-XiménezMyriam Aguilar PérezAlicia Gomez-LopezAranzazu Sancho-LópezCristina López García-GalloGema Díaz NuevoElena Diago-SempereBelén Ruiz-AntoránCristina Avendaño-SoláPiedad Ussetti-Gilnull null
Published in: Antimicrobial agents and chemotherapy (2023)
Isavuconazole's (ISA) pharmacokinetics was studied among lung transplant recipients to evaluate its bronchopulmonary penetration. This study included 13 patients and showed mean serum concentrations of 3.30 (standard deviation [SD] 0.45), 5.12 (SD 1.36), and 6.31 (SD 0.95) at 2 h, 4 h, and 24 h respectively. Mean concentrations in the epithelial lining fluid were 0.969 (SD 0.895), 2.141 (SD 1.265), and 2.812 (SD 0.693) at the same time points. ISA is a drug with a tolerable safety profile that achieves adequate concentrations in the lung.
Keyphrases
  • ejection fraction
  • newly diagnosed
  • emergency department
  • patient reported outcomes